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Accepted 26 August 2017Background. There is a need for early markers to track and predict the development of
type 2 diabetes mellitus (T2DM) from the state of normal glucose tolerance through
prediabetes. In this study we tested whether the plasma molecular lipidome has biomarker
potential to predicting the onset of T2DM.
Methods. We applied global lipidomic profiling on plasma samples from well-
phenotyped men (107 cases, 216 controls) participating in the longitudinal METSIM study
at baseline and at five-year follow-up. To validate the lipid markers, an additional study
with a representative sample of adult male population (n = 631) was also conducted. A total
of 277 plasma lipids were analyzed using the lipidomics platform based on ultra-
performance liquid chromatography coupled to time-of-flight mass spectrometry. Lipids
with the highest predictive power for the development of T2DM were computationally
selected, validated and compared to standard risk models without lipids.
Results. A persistent lipid signature with higher levels of triacylglycerols and diacyl-
phospholipidsaswellas lower levelsofalkylacylphosphatidylcholineswasobserved inprogressors
to T2DM. Lysophosphatidylcholine acyl C18:2 (LysoPC(18:2)), phosphatidylcholines PC(32:1),
PC(34:2e) and PC(36:1), and triacylglycerol TG(17:1/18:1/18:2) were selected to the full model that
included metabolic risk factors and FINDRISC variables. When further adjusting for BMI and age,Keywords:
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2 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 7 8 ( 2 0 1 8 ) 1 – 1 2these lipids had respective odds ratios of 0.32, 2.4, 0.50, 2.2 and 0.31 (all p < 0.05) for progression to
T2DM. The independently-validated predictive power improved in all pairwise comparisons
between the lipid model and the respective standard risk model without the lipids (integrated
discrimination improvement IDI > 0; p < 0.05). Notably, the lipidmodels remainedpredictive of the
development of T2DM in the fasting plasma glucose-matched subset of the validation study.
Conclusion. This study indicates that a lipid signature characteristic of T2DM is present
years before the diagnosis and improves prediction of progression to T2DM. Molecular lipid
biomarkers were shown to have predictive power also in a high-risk group, where standard
risk factors are not helpful at distinguishing progressors from non-progressors.© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic
disorder characterized by hyperglycemia, which results from
impaired insulin secretion of pancreatic β-cells and from ineffec-
tive cellular response to insulin [1]. Diabetes is preceded by a
prodromal phase that may last many years. Prediabetes is
currently characterized, once glucose has become elevated, by
impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or
both. IFGand IGTarenot equivalent bymetabolic termsand,most
likely, reflect different pathophysiological states leading to T2DM
[2]. Consequently, they may require different treatments.
The onset of T2DM in prediabetic individuals can be
prevented—or at least delayed—by pharmacological or life-
style interventions [3]. Ideally, knowledge about the underly-
ing pathophysiological characteristics associated with either
fasting or postprandial glucose dysregulation could be helpful
at optimizing the efficacy of treatments [4]. Therefore, there is
a need for predictive tools enabling the efficient and accurate
tracking of progression from a state of normal glucose
tolerance (NGT) to pre-diabetes (IFG, IGT or both) and finally
to T2DM. So far, several T2DM risk models and scores have
been developed as prognostic tools. These models are mainly
based on established risk factors of T2DM and lack the
specificity needed for the use in clinical practice [5–7]. A
comprehensive review [7] of almost one hundred T2DM
predictive models showed that the most typical non-lipid
risk factors included in a T2DM risk prediction model are the
age, obesity, gender, family history, blood pressure, FPG, 2-h
postprandial plasma glucose and glycated hemoglobin
(HbA1c). The most typical lipid-based risk factors are the
HDL-C, LDL-C and triglycerides (TG).
Several metabolites have indeed been found to be associ-
ated with dysglycemia and T2DM [8]. Fasting plasma levels of
branched-chain amino acids and aromatic amino acids have
been reported to be associated with the increased risk of
T2DM in prospective studies [9,10]. Population-based studies
have revealed that glycine, lysophosphatidylcholine acyl
C18:2 (LysoPC(18:2)), acetylcarnitine [11], α-hydroxybutyrate
[12] as well as specific choline-containing phospholipids [13]
are predictive of abnormalities in glucose tolerance. Recently,
a novel IGT test with metabolite markers was reported [14,15].
Knowledge about global changes in the plasma lipidome
during the progression from NGT or prediabetes to T2DM still
is limited. The potential of plasma lipids as predictors of
T2DM has not been thoroughly validated. A recent targetedlipidomic profiling from the ADVANCE study demonstrated [16]
the potential of circulating molecular lipids as biomarkers of
cardiovascular risk in T2DM. Specific lipids such as TGs with low
carbon number and low double bond content, which also
characterize increased liver fat content [17], have been associated
with insulin resistance and elevated risk of T2DM [18,19]. Specific
plasma ceramides, which are elevated in obese subjects with
T2DM, have also been found [20] to reflect the severity of insulin
resistance. Moreover, ceramides present in LDL have been found
[21] to be elevated in T2DM, promoting inflammation and skeletal
muscle insulin resistance.
The plasma lipidome is sensitive to the amount of liver fat
and has been shown [17] to predict non-alcoholic fatty liver
disease (NAFLD). Since liver fat is a risk factor of T2DM [22], we
hypothesize that aberrations in the levels of plasma molec-
ular lipids could also be independent predictors of T2DM. To
test this hypothesis, we applied a global lipidomic profiling
approach to a prospective study of well-phenotyped male
subjects with an aim (a) to identify a lipid signature that
precedes T2DM, and (b) to build and validate a lipid-based
model that can predict progression to T2DM in adult men.2. Methods
2.1. Participants
A total of 10,197 men participated in the population-based
METSIM (METabolic Syndrome In Men) Study [23]. The 5-year
follow-up data were available for 3408 men. Glucose tolerance
status was assessed according to the ADA criteria [23] on plasma
glucose levels in OGTT and HbA1c measurements. In total, 2916
men were non-diabetic at baseline both by the OGTT and
HbA1c criteria (FPG < 7.0 mmol/L and 2HPG < 11.1 mmol/L and
HbA1c < 6.5%). The study protocol was approved by the Ethics
Committee of the University of Eastern Finland and Kuopio
University Hospital. The studywas conducted in accordancewith
the principles of the Helsinki Declaration. Each participant
provided a written informed consent.
2.2. Study Design
Participants were divided into a discovery set (n = 323) and a
validation set (n = 631) to fit and validate the models,
respectively. The baseline clinical characteristics for both
groups are shown in Table 1.
Table 1 – Baseline biochemical measurements and clinical characteristics of the METSIM study participants (n = 958)
selected for the discovery set (n = 323) and for the validation set (n = 631).
Discovery set Validation set
Non progressors Progressors Non progressors Progressors
NGT Pre-diabetic All All NGT Pre-diabetic All All
n 129 87 216 107 127 481 608 23
Age (years) 59.3 ± 5.1 60.8 ± 5.4 59.9 ± 5.3 59.0 ± 5.7 52.2 ± 5.0 53.9 ± 4.4 53.6 ± 5.0 54.2 ± 4.2
Family history of
diabetes (%)
44.2 46.0 44.9 59.8* 48.8 52.2 51.5 52.2
BMI (kg/m2) 26.1 ± 2.4 26.2 ± 2.1 26.2 ± 2.3 28.6 ± 3.8* 25.1 ± 2.8 26.4 ± 3.1 26.1 ± 3.2 29.4 ± 4.2*
Waist circumference (cm) 95.1 ± 7.2 95.6 ± 6.5 95.3 ± 6.9 102.4 ± 10.4* 98.3 ± 5.9 100.3 ± 4.7 99.9 ± 5.9 103.7 ± 8.1*
Systolic blood pressure
(mm Hg)
132.1 ± 15.1 133.9 ± 15.3 132.8 ± 15.2 143.0 ± 16.0* 129.1 ± 12.5 133.8 ± 14.1 132.8 ± 14.0 143.6 ± 17.7*
Diastolic blood pressure
(mm Hg)
84.3 ± 8.6 85.1 ± 9.8 84.6 ± 9.1 89.8 ± 8.6* 84.1 ± 7.7 87.3 ± 8.5 86.6 ± 8.4 94.2 ± 9.9*
Fasting plasma glucose
(mmol/l)
5.2 ± 0.2 5.1 ± 0.2 5.2 ± 0.2 6.0 ± 0.5* 5.3 ± 0.2 5.8 ± 0.2 5.7 ± 0.4 6.2 ± 0.5*
2-hour plasma glucose
(mmol/l)
5.0 ± 0.8 5.1 ± 1.0 5.0 ± 0.9 8.1 ± 2.0* 5.0 ± 1.2 5.8 ± 1.1 5.6 ± 1.5 8.2 ± 1.8*
Fasting plasma insulin
(mU/l)
5.3 ± 2.8 5.7 ± 2.7 5.5 ± 2.8 11.9 ± 7.0* 5.6 ± 2.9 7.6 ± 3.6 7.2 ± 4.5 12.3 ± 5.8*
2-hour plasma insulin
(mU/l)
28.7 ± 25.5 31.1 ± 20.7 29.7 ± 23.6 100.3 ± 68.4* 32.0 ± 31.2 41.3 ± 26.6 39.4 ± 27.8 97.6 ± 64.0*
Hemoglobin A1C (%) 5.5 ± 0.2 5.8 ± 0.2 5.6 ± 0.3 6.3 ± 0.8* 5.4 ± 0.2 5.8 ± 0.1 5.6 ± 0.3 5.9 ± 0.4*
LDL cholesterol (mmol/l) 3.4 ± 0.9 3.3 ± 0.8 3.4 ± 0.8 3.3 ± 0.8 3.6 ± 0.8 3.5 ± 0.7 3.5 ± 0.8 3.5 ± 1.0
HDL cholesterol (mmol/l) 1.5 ± 0.4 1.6 ± 0.4 1.5 ± 0.4 1.3 ± 0.4 1.5 ± 0.4 1.5 ± 0.4 1.5 ± 0.4 1.4 ± 0.4
Total triacylglycerols
(mmol/l)
1.1 ± 0.5 1.1 ± 0.5 1.1 ± 0.5 1.9 ± 1.2* 1.3 ± 0.7 1.4 ± 0.9 1.4 ± 0.8 1.8 ± 0.9*
Fat mass (%) 23.2 ± 6.4 24.5 ± 6.3 23.7 ± 6.4 25.5 ± 6.1 18.9 ± 3.8 20.4 ± 4.1 20.0 ± 4.4 24.1 ± 4.5*
Serum ALT (U/l) 24.6 ± 12.5 24.9 ± 10.5 24.8 ± 11.7 40.0 ± 25.4* 27.5 ± 15.5 31.2 ± 18.5 30.4 ± 18.5 41.8 ± 18.5*
Plasma hs-CRP (mg/l) 1.7 ± 2.6 1.7 ± 2.5 1.7 ± 2.3 2.2 ± 2.4 1.1 ± 2.8 1.8 ± 1.3 1.7 ± 1.3 2.3 ± 1.3
Data are presented in mean ± SD for continuous variable or percentages for categorical variables. ANOVA followed by post hoc Tukey
comparisons for continues variables and Chi-squared test (χ2) for categorical variables (p < 0.001), *non-progressor significantly different from
progressor to type 2 diabetes.
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cases (i.e., progressing individuals who were non-diabetic at
baseline but developed T2DM during the five-year follow-up),
and 216 age-matched controls (i.e., non-progressing individuals
who were non-diabetic at baseline and did not develop T2DM
during the five-year follow-up). The criteria for a new-onset
T2DM were FPG ≥ 7.0 mmol/L and/or 2HPG ≥ 11.1 mmol/L and/
or HbA1c ≥ 6.5%, and/or a physician-based diagnosis and anti-
diabetic medication started between the baseline and follow-up
examinations. Participants with incident T2DM, diagnosis of
T2DM between baseline and follow-up (n = 54) or greatest
glucose AUC at follow-up (n = 53 of the cases diagnosed with
T2DM at follow-up) were included as T2DM progressors for the
present study. A total of 504 participants were normoglycemic
(FPG < 5.6 mmol/L, 2HPG < 7.8 mmol/L and HbA1c < 6.5%) both
at the baseline and follow-up examinations. Out of these, 216
age-matched subjects from the top-end of the body mass index
(BMI) distribution and from the lower end of the distribution of
glucose area under the glucose curve (AUC) in anOGTT at follow-
upwere included as T2DMnon-progressors for the discovery set.
There were no cases of IFG or IGT among the non-progressors.
Non-diabetic subjects (by both theOGTT andHbA1c criteria at
baseline) from the remaining 1593 participants of the METSIM
Study were randomly selected to the validation set. Clinical data
at baseline and follow-up were available for 631 subjects. T2DMnon-progressors in the validation set were characterized by a
broad distribution of glucose tolerance with 21% NGT and 79%
pre-diabetic subjects (77% IFG; 2% IGT; 7% IFG + IGT; 14% with
5.7 < HbA1c(%) < 6.4; Supplementary Fig. S1). T2DMprediction in
the validation set was tested in the full set, in the FPG-matched
set of non-progressors and progressors, and in a set including
only progressors and prediabetic non-progressors.
An unthawed plasma sample (EDTA) was available from all
participants at baseline. An additional plasma sample at follow-
up was only available from the participants in the discovery set.
Plasmawas separated by centrifugation (1300 ×g; 15 min; +4 °C),
frozen immediately at −80 °C, and stored until analysis.
2.3. Measurements
Clinical and biochemical measurements were performed as
described in the Supplementary Methods S2.3.1 and earlier [23].
Molecular serum lipidswere analyzed at VTTTechnical Research
Centre of Finland (Espoo, Finland) with amethodology described
in the Supplementary Methods S2.3.2 and earlier [24].
2.4. Statistical Analysis
Clinical characteristics of the study participants are presented
as mean ± standard deviation (SD) for continuous variables
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continuous and categorical variables were computed using
Student's t-test and chi-squared test, respectively.
Lipidomic data were base-2 log-transformed, and scaled to
zero mean and unit variance. Gaussian mixture model
(mclust2 package [25] for R) was fit on the data from the
discovery set at baseline to identify coherent clusters of lipids.
The number of clusters was selected based on the Bayesian
information criterion (BIC) of the model.
Linear mixed-effect models (lme4 package [26] for R) were fit
to the clustered discovery set at baseline to identify coherent
early-timedifferences betweenprogressors andnon-progressors.
Each model was adjusted for BMI and age, and included one of
the lipid clusters as the dependent variable, the group label
(progressor/non-progressor) as the fixed effect. Overall group
differences were tested using F-statistic and post-hoc analyses
were done using Tukey's all-groups comparisons.
Average profiles of the lipid clusters were compared between
the groups after scaling all the data based on the lipid-specific
meanandstandarddeviationof thebaselineNGTnon-progressors
from the discovery set. Paired t-test was used to compare cluster
profiles between the baseline and five-year follow-up time points
in the discovery set. Non-paired t-test was used for comparing
baseline cluster profiles between progressors and non-progressors
in the discovery and validation sets (p-value < 0.01).
2.5. Predictive Modeling of Progression to Type 2 Diabetes
Logistic regression models were fit with the aim of predicting
the progression to T2DM (i.e., the progressor/non-progressor
label as the dependent variable of themodel). Predictive lipids
were selected in four ways: independently (the “Lipids”
model), in combination with the Finnish Diabetes Risk Score
variables (“Lipids and FINDRISC”), in combination with the
clinical marker variables of metabolic syndrome (FPG, HDL-C,
systolic blood pressure and total triacylglycerols; the “Lipids
and MS” model), and in combination with both the FINDRISC
and metabolic syndrome variables (“Lipids, FINDRISC and
MS”). These four lipid models were compared to their
respective counterparts without the lipid variables (“Ran-
dom,” “FINDRISC,” “MS,” and “FINRISC and MS,” respectively).
Lipid variables with the highest predictive power at the
baseline measurement were forward-selected based on the
area under the receiver operating characteristic curve (AUC)
of the prediction of left-out samples in nested five-fold cross-
validation [27] using the discovery set. Only lipid variables
were selected; the FINDRISC and MS variables were always
included in the models where their inclusion is stated. The
FINDRISC model was fixed with the statistically significant
coefficients reported in the original study [5].
Following the guideline [28] for the ratio between the
limiting sample size and model complexity for a binary
outcome variable, models with their top-five-selected lipid
variables over the cross-validation were further tested with
the independent validation set. The models were fit using the
bootstrap-sampled [27] discovery set at baseline, and tested
by predicting the validation set. Both for the cross-validated
prediction of the discovery set and for the bootstrapped
prediction of the validation set, the 95% confidence intervals
for the AUC and the p-values for the test of differencebetween the AUCs were computed based on the empirical
distributions [29] over 200 bootstrap randomizations. Further,
integrated discrimination improvement (IDI) [30] with 95%
confidence intervals and the test of positive IDI between lipid
and non-lipid models were computed in the same way.
The models were further tested with the validation set sub-
sampled in two different ways: first, with FPG-matched balanced
set of progressors and non-progressors (n = 23 and n = 23,
respectively; Supplementary Table S1) in order to eliminate the
effect of FPGas a confounding factor, and second,withprogressors
and prediabetic non-progressors only (i.e., high-risk subjects; n =
23 and n = 481, respectively). Difference between progressors and
non-progressors was computed for each of the selected lipids in
eachof thedata sets aswell as in thehigh-risk subset and the FPG-
matched subset of the validation set. Additionally, the difference
wascomputed ina subsetof thediscovery setwithanormal FPGat
baseline (n = 17 progressors and matched non-progressors; Sup-
plementary Table S2). Details of these sub-sampling experiments
are explained in Supplementary Methods S2.5.3. Results
3.1. Study Setting
Biochemical and clinical characteristics of subjects in the
discovery set (n = 323) and the validation set (n = 631) are
presented in Table 1. As expected, progressors were charac-
terized by significantly higher levels of traditional risk factors
of T2DM than the non-progressors.
A totalof277molecular lipidswere identifiedboth in thediscovery
set and in the validation set. These lipids were glycerophospholipids
(PL), such as diacyl phosphatidylcholines (PC), alkylacyl phosphatidyl-
cholines (PCe), phosphatidylethanolamines (PE), alkylacyl phosphati-
dylethanolamines (PEe), lysophosphatidylcholines (LysoPC) and
lysophosphatidylethanolamines (LysoPE), triacylglycerols (TG), choles-
terol esters (ChoE), sphingomyelins (SM) and ceramides (Cer).
3.2. Baseline Lipid Profiles Associated With Progression to
Type 2 Diabetes
The high degree of co-regulation in the lipidomewasmodeled
with unsupervised probabilistic clustering fit to the baseline
lipidomic data of the discovery set. The model identified 12
lipid clusters (LCs; Table 2), which to a large extent follow
functional and structural groups (Supplementary Table S3).
Already fiveyearsbefore thediagnosis,markeddifferences in the
lipidome were observed between progressors and non-progressors
(Fig. 1). The lipidomic signature of progressors was characterized by
elevated levels of four TG clusters (LC9 to LC12) and one PL cluster
(LC8), and an opposite pattern of the ether PL (alkylacyl phospho-
lipids) cluster (LC5). Several established risk markers of T2DM (BMI,
waist circumference, HDL, LDL, total TG, and ALT levels) were
positively correlated with the TG clusters (LCs 9–12), and negatively
correlated with the ether PL cluster (LC5; Supplementary Fig. S2).
3.3. Lipidomic Profiles at the Five-Year Follow-Up Visit
The persistence of the early lipidomic signature characteriz-
ing progression to T2DM was assessed by comparing the
Table 2 – Summary of the lipid clusters, showing the cluster name, number of lipids in the cluster, lipid groups in the
cluster, p-value of the difference between progressors and non-progressors in the discovery set at baseline, and example
lipid species in the cluster.
Cluster
name
Cluster
size
Cluster description p-Value Examples of lipid species
LC1 25 SM, Cer, PCs, PE, TG 0.22 SM(d18:1/16:1), PC(32:0), PC(34:2e), PE(38:2), TG(53:7)
LC2 4 Cholesterol esters 0.77 ChoE(18:1), ChoE(18:2), ChoE(20:4), ChoE(20:5)
LC3 12 LysoPC and LysoPE 0.78 LysoPC(14:0), LysoPC(18:2), LysoPE(18:0), LysoPE(18:2)
LC4 27 PUFA-containing PC, PE, PCe, PEe, LysoPC 0.34 PC(18:0/22:6), PC(40:6e), PE(40:6), PE(40:7e), LysoPC(22:6)
LC5 30 Alkylacyl (ether) phospholipids 3 × 10−3 PC(32:0e), PC(38:3e), PC(40:5e), PE(36:2e), PE(40:8e)
LC6 14 Arachidonic acid containing- PC, PCe, and PEe 0.05 PC(16:0/20:4), PC(p18:0/20:4), PE(38:4e), PE(p18:0/20:4)
LC7 12 Polyunsaturated long chain TG 0.05 TG(50:5), TG(52:6), TG(54:6), TG(54:7)
LC8 40 PC and PE 1 × 10−4 PC(30:0), PC(40:5), PE(36:4), PE(40:6)
LC9 28 Highly polyunsaturated long chain TG 1 × 10−3 TG(22:6/18:1/18:1), TG(56:7), TG(58:10), TG(62:12)
LC10 13 Mono- and poly- unsaturated long chain TG 2 × 10−6 TG(50:3), TG(52:7), TG(58:7)
LC11 42 Saturated and low unsaturated medium to
long chain TG
1 × 10−7 TG(14:0/16:0/16:0), TG(16:0/18:0/12:0), TG(16:0/18:0/18:1)
LC12 30 Abundant TG in plasma 9 × 10−11 TG(16:0/18:1/18:1), TG(55:5), TG(58:6)
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profiles among the progressors, prediabetic non-progressors
and NGT non-progressors of the discovery set (n = 107, 87 and
129, respectively). NGT non-progressors were similar to
prediabetic non-progressors by their lipidomic profile. There
were no significant differences between the groups either at
baseline or at the five-year follow-up (Fig. 2). On the other
hand, progressors had persistently higher levels of TGs (LC9–
12), diacyl PLs (LC8), and lower levels of PCe lipids (LC5) when
compared to NGT and pre-diabetic non-progressors. Specifi-
cally, the distinctive baseline signature observed in
progressors remained unchanged at the five-year follow-up
with no significant changes in the lipid cluster levels over the
five-year period (Fig. 2). The only significant changes over the-0.60
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Fig. 2 –Mean levels of the lipid clusters for normal glucose-tolerant (NGT) non-progressors (white bars), prediabetic non-progressors
(striped bars) and progressors to type 2 diabetes (black bars) in the discovery set (a) at baseline and (b) at five-year follow-up. For the
simultaneous interpretation of group and time differences, the cluster levels are scaled based on the cluster-specific mean and
standard deviation of theNGTnon-progressor group at baseline,which is the reference group. The baseline and the five-year follow-
up time points were compared with the paired two-sided t-test (asterisk marker for p < 0.01). The groups were compared within a
time point with the non-paired two-sided t-test (marker “a” indicates a significant difference between progressors and NGT non-
progressors; marker “b” indicates significant difference between progressors and prediabetic non-progressors; p < 0.01). Error bars
show the standard error of the mean. The clusters are summarized in Table 2.
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In total, 11 lipids were selected to the four prediction models
(Table 3). The lipids that predicted progression to T2DM in the
cross-validated discovery set were the LysoPC(18:2), three TGs
(TG(50:1), TG(54:5), TG(56:4)) and the ether lipid PC(42:6e). The
cross-validated prediction performance of the “Lipids”model,
which consisted of these selected lipids only, was better than
the random baseline (cross-validated area under the receiver
operating characteristic curve, AUC “Lipids” = 0.842; AUC
“Random” = 0.50; integrated discrimination improvement,
IDI = 0.359; p < 0.05 for the test of positive IDI; Table 4;
Supplementary Fig. S3).
When the FINDRISC variables were included as predictors,
the selected lipids were the same as with the “Lipids” model
except for the TG(51:5), which replaced the TG(56:4). The
cross-validated prediction performance of the “Lipids and
FINDRISC” model consisting of the selected lipids and the
FINDRISC variables was better than the model with the
FINDRISC variables only (AUC 0.864 vs. 0.755; IDI 0.282;
p < 0.05).When the metabolic syndrome variables were included as
predictors, the selected lipids were the previously-selected
LysoPC(18:2), PC(32:1), PC(34:2e), TG(17:1/18:1/18:2) and
TG(50:5). The cross-validated prediction performance of the
“Lipids and MS” model consisting of the selected lipids and
the MS variables was better than the model with the MS
variables only (AUC 0.967 vs. 0.956; IDI 0.049; p < 0.05).
When both the FINDRISC and metabolic syndrome vari-
ables were included as predictors, the selected lipids were the
same as with the “Lipids and MS” model except for the
TG(50:5), which was replaced by the PC(36:1). The cross-
validated prediction performance of the “Lipids, FINDRISC
and MS” model consisting of the selected lipids and the
FINDRISC and MS variables was better than the model with
the FINDRISC and MS variables only (AUC 0.967 vs. 0.955;
IDI = 0.059; p < 0.05).
3.5. Validation of the Predictive Model
The models fit with the discovery set were then tested by
predicting the validation set. The findings with the discovery
Fig. 3 – Standardized difference in triacylglycerols (TG) between progressors and non-progressors (Glass' delta effect size; y-axis) in the
discoveryset, shownasa functionof thenumberofacyl chaindoublebondsatbaselineand follow-up (top-left andtop-right, respectively),
and as a function of the number of acyl chain carbon atoms at baseline and follow-up (bottom-left and bottom-right, respectively).
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mentary Fig. S4): the “Lipids” model was better than the
random baseline (area under the receiver operating charac-
teristic curve, AUC “Lipids” = 0.776 vs. AUC “Random” = 0.50;
integrated discrimination improvement, IDI = 0.259; p < 0.05
for the test of positive IDI), the “Lipids and FINDRISC” model
was better than the “FINDRISC” model (AUC 0.757 vs. 0.651;
IDI 0.213; p < 0.05), the “Lipids and MS”model was better than
the “MS” model (AUC 0.835 vs. 0.800; IDI 0.065; p < 0.01), and
the “Lipids, FINDRISC and MS” model was better than the
“FINDRISC and MS” model (AUC 0.840 vs. 0.813; IDI 0.89;
p < 0.05).When testing the models with the FPG-matched subset of
the validation set, the improvement in the predictive power of
the lipids remained significant in all comparisons while the
FPG was ruled out as a confounding factor (Table 4; Supple-
mentary Fig. S5): the “Lipids” model was better than the
random baseline (AUC “Lipids” = 0.698 vs. AUC “Random” =
0.50; IDI = 0.203; p < 0.05), the “Lipids and FINDRISC” model
was better than the “FINDRISC” model (AUC 0.692 vs. 0.561; IDI
0.178; p < 0.05), the “Lipids and MS” model was better than the
“MS” model (AUC 0.597 vs. 0.560; IDI 0.049; p < 0.05), and the
“Lipids, FINDRISC andMS”model was better than the “FINDRISC
and MS”model (AUC 0.616 vs. 0.558; IDI 0.067; p < 0.05).
Table 3 – List of lipids selected to the models predicting progression to T2DM based on the baseline observations.
Lipid name Model
Lipids Lipids and FINDRISC Lipids, FINDRISC and MS Lipids and MS
LysoPC(18:2) X X X X
PC(32:1) X X
PC(34:2e) X X
PC(42:6e) X X
TG(17:1/18:1/18:2) X X
TG(50:1) X X
TG(54:5) X X
PC(36:1) X
TG(50:5) X
TG(51:5) X
TG(56:4) X
Selection of a lipid (row) to a model (column) is marked by a cross (“X”).
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and prediabetic non-progressors), the improvement in the
predictive power of the lipids remained significant in all the
comparisons (Table 4; Supplementary Fig. S6): the “Lipids”model
was better than the random baseline (AUC “Lipids” = 0.749; AUC
“Random” = 0.50; IDI = 0.244; p < 0.05), the “Lipids and FINDRISC”
modelwas better than the “FINDRISC”model (AUC 0.740 vs. 0.639;
IDI 0.198; p < 0.05), the “Lipids andMS”modelwas better than the
“MS” model (AUC 0.802 vs. 0.766; IDI 0.067; p < 0.05), and the
“Lipids, FINDRISC and MS”model was better than the “FINDRISC
and MS”model (AUC 0.811 vs. 0.780; IDI 0.095; p < 0.05).
In 9 out of 11 lipids selected by the models, the direction of
difference between progressors and non-progressors wasTable 4 – Prediction performance of the models (rows) in the fo
validation set as well as the high-risk and FPG-matched subse
a) Area under receiver operating characteristic (AUC) curve
Model Data set
Discovery Validation, all
Lipids, FINDRISC and MS 0.967 (0.944, 0.974) 0.840 (0.823, 0.8
Lipids and MS 0.967 (0.960, 0.974) 0.835 (0.814, 0.8
FINDRISC and MS 0.955 (0.945, 0.96) 0.813 (0.796, 0.8
MS 0.956 (0.949, 0.959) 0.800 (0.789, 0.8
Lipids 0.842 (0.829, 0.851) 0.776 (0.757, 0.7
Lipids and FINDRISC 0.864 (0.852, 0.874) 0.757 (0.719, 0.7
FINDRISC 0.755 (0.755, 0.755) 0.651 (0.651, 0.6
Random 0.500 (0.500, 0.500) 0.500 (0.500, 0.5
b) Integrated discrimination improvement (IDI) of a lipid model
Model Model
Discovery Validation, all
Lipids 0.359 (0.344 0.368) 0.259 (0.218 0.30
Lipids and FINDRISC 0.282 (0.266, 0.296) 0.213 (0.175, 0.2
Lipids and MS 0.059 (0.041, 0.075) 0.089 (0.003, 0.1
Lipids, FINDRISC and MS 0.049 (0.033 0.061) 0.065 (0.023, 0.1
Models are assessed by area under receiver operating characteristic curve
counterparts by integrated discrimination improvement (IDI; b). Positive
lipid counterpart model in each data set with p < 0.05.fully consistent in the discovery set at baseline and at
follow-up, in the validation set, as well as in the FPG-
matched subsets of the discovery and validation sets (Fig. 4).
For four of the lipids—PC(32:1), PC(36:1), TG(50:1) and
TG(50:5)—the difference between progressors and non-
progressors was strongest in the matched normal-FPG subset
of the discovery set. Also for PC(34:2e) and PC(42:6e), the
difference was stronger in the normal FPG-subset of the
discovery set than the entire discovery set. This finding gives
indication that the identified lipidomic pattern is present
across the stages of the development of T2DM. Especially
changes in the six aforementioned lipids may be indicative of
metabolic changes that eventually lead to T2DM.llowing data sets (columns): discovery set (cross-validated),
ts of the validation set.
Validation, high-risk Validation, FPG-matched
54) 0.811 (0.787, 0.824) 0.616 (0.561, 0.667)
53) 0.802 (0.779, 0.821) 0.597 (0.384, 0.645)
28) 0.780 (0.756, 0.793) 0.558 (0.444, 0.592)
10) 0.766 (0.748, 0.775) 0.56 (0.444, 0.582)
85) 0.749 (0.744, 0.769) 0.698 (0.605, 0.781)
77) 0.740 (0.710, 0.763) 0.692 (0.594, 0.779)
51) 0.639 (0.639, 0.639) 0.561 (0.469, 0.660)
00) 0.500 (0.500, 0.500) 0.500 (0.500, 0.500)
compared to the respective non-lipid model
Validation, high-risk Validation, FPG-matched
4) 0.244 (0.205 0.288) 0.203 (0.118, 0.279)
48) 0.198 (0.164, 0.231) 0.178 (0.073, 0.273)
65) 0.095 (−0.002 0.177) 0.067 (−0.001 0.141)
20) 0.067 (0.016, 0.127) 0.049 (0.001 0.099)
(a). Lipid marker models are compared to their respective non-lipid
IDI means improvement; all lipid models were better than their non-
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Fig. 4 – Standardized differences of the selected marker lipids between progressors and non-progressors (Glass' delta; y-axis)
in the data sets of the study: the matched normal-FPG subset of the discovery group at baseline (dark blue squares), the entire
discovery set (light blue diamonds), the discovery set at five-year follow-up (green circles), the FPG-matched subset of the
validation set at baseline (red triangles) and the entire validation set at baseline (orange triangles). Error bars show the 95%
quantiles of the difference, computed over bootstrap resamples. In progressors, five of the lipids have a change that is
consistent over all the data sets: two of the selected lipids, LysoPC(18:2) and PC(34:2e), have a consistent decrease, and three
triacylglycerols, TG(50:1), TG(54:5) and TG(56:4), have a consistent increase. Four lipids, PC(32:1), PC(36:1), TG(50:1) and TG(50:5)
are potential early markers, since their differences between progressors and non-progressors are strongest in the matched
normal-FPG subset of the discovery set. Abbreviations of themodels, for which the lipid was selected, are shown on the x-axis
label along with the lipid name (L: Lipids; LF: Lipids and FINDRISC; LFM: Lipids, FINDRISC and MS; LM: Lipids and MS).
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Risk prediction models for T2DM could be helpful for clinical
decision making by identifying subjects that are likely to
benefit from an early intervention. In this study, we identified
a lipid molecular signature that improves the prediction of
progression to T2DM compared to established risk factors.
Overall, baseline levels of TGs and PCs were associated with
progression to T2DM while ether PCs were inversely associ-
ated. This lipid signature persisted over the five-year follow-
up period. Results with the validation cohort and its subsets
indicate that the prediction models have the potential for
generalizing beyond the present study.
Our findings are in agreement with several previous
studies: In the KORA and EPIC-Postdam cohorts [11,13],
similar associations were observed between PCs, ether PCs,
LysoPCs and the risk of T2DM. LysoPC(18:2) was inversely
associated with dysglycemia and T2DM risk in the RISC and
Botnia cohorts, respectively [15]. Association of TGs with the
progression to T2DM, particularly the TGs of low double bond
content, is in agreement with findings from the Framingham
Heart Study [18]. Our results are also in agreement with the
lipid-based classification results from the AusDiab study [31],where the inclusion of plasmaDGs and TGs improved prediction
performance compared to a model based on the total TGs and
HbA1c. These studies, along with the present study, provide
increasing evidence for the distinct molecular lipid profile in
individuals,whoare about to progress toT2DM. Furthermore, the
results indicate that lipids can improve prediction performance
as compared to established risk factors.
In agreement with previous studies, we have demonstrat-
ed that the distinct lipid profile in progression to T2DM can
also be used for stratifying subjects within a risk group.
Compared to bulk blood cholesterol and total TGs, a set of
molecular lipid species may provide a more detailed view of
the altered lipid homeostasis in subjects with T2DM in
development. As a novel finding, we also found that the
lipid profile associated with diabetes was persistent in time.
To further test the utility of lipid predictors independently of
FPG, we demonstrated that themodels remained predictive of
T2DM in an FPG-matched subset of the validation cohort.
We found that several phospholipids were associated with
progression to T2DM. Phospholipids, such as PCs, ether PCs
and LysoPCs, are the main components of the surface layer of
lipoproteins [19]. Specifically, LysoPCs are predominantly
found in the HDL fraction of healthy subjects [32,33]. It is
well-known that hyperglycemia caused by T2DM leads to
10 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 7 8 ( 2 0 1 8 ) 1 – 1 2alterations in lipid metabolism, including enhanced HDL
clearance, decreased apoA-1 transcription and accelerated
HDL glycation [34]. Lipid and structure-function studies
suggest that alterations of the lipidome and the negative-
charged enrichment of phospholipids in the smaller HDL sub-
fraction play a crucial role in HDL dysfunctionality, particu-
larly in T2DM. A recent study [35] demonstrated that in T2DM
the HDL particles have a different surface polarity, which is
associated with different lipid composition in the HDL
particles. The authors of this study hypothesized that the
decreased size forces CEs and TGs to emerge from the HDL
core to the surface, making the outer surface of HDL more
hydrophobic.
In agreement with several recent studies, we found that
LysoPC(18:2) was decreased in subjects that progressed to
T2DM [11,15,36]. LysoPCs are formed either by phospholipase
A2-induced hydrolysis or by oxidation of PCs in phospholipid-
containing structures, such as LDL and cell membranes. The
decreased levels of LysoPC(18:2) observed in this study could
result either (1) from the decreased activity of PLA2 [37], (2)
from the increased breakdown or enhanced clearance of the
lipid from circulation by metabolically active tissues, or (3)
from the influence of dietary factors. In the present study, the
total LysoPC levels were not decreased, rendering it unlikely
that the PLA2 activity would be decreased. On the other hand,
a recent study [36] found that nutrition can influence
circulating LysoPC levels: broad decreases in circulating
LysoPCs were observed in fat-fed mice while changes of few
individual LysoPCs were observed in the liver, muscle and
adipose tissues. In agreement with this explanation, in our
data, LysoPC(18:2) was correlated with its precursor PCs that
are associated with fat intake [38].
In a more specific T2DM risk stratification study [39],
LysoPC(18:2)was reportedasaselectivemarkerof isolated impaired
glucose tolerance, which is a high-risk state of T2DM. LysoPC(18:2)
did not predict isolated impaired fasting glucose in that study. On
the other hand, decreased levels of LysoPC(18:2) have also been
reported to be inversely associatedwith obesity [40] aswell as with
BMI and age [41]. Taken together, while decreased levels of
LysoPC(18:2) have been found to be associated with increased risk
of T2DM in several studies, includingours,more studies areneeded
in order to clarify themechanisms behind this association.
In agreement with previous studies [13,42], we also
observed an inverse association between T2DM and ether-
linked PCs. This may be explained at least in part by the
enrichment of ether phospholipids in the HDL fraction [19,32].
T2DM has been found to be associated with both increased
oxidative stress and inflammation. The concentrations of PE
plasmalogens, for instance, were earlier found [43] to be
decreased in T2DM subjects while hydroxylated FAs were
increased. Among the selected predictor lipids, PC(42:6e) was
down-regulated in progressors. A more unsaturated PC with the
same carbon number has recently been reported [44] as down-
regulated in another high-risk group—American Indians—who
developed T2DMafter a similar 5.5 year follow-up. The other two
selected predictive phosphatidylcholines—PC(32:1) and
PC(34:2e)—were also reported [11] with up-regulation and
down-regulation, respectively, inprogressors of theKORAcohort.
TGs with low double bond content are predictive of NAFLD
[17] and insulin resistance [19]. The association of these TGswiththe progression of T2DM may, thus, reflect increased de novo
lipogenesis, which is increased in NAFLD [45,46]. Our study
supports the hypothesis that lipotoxicity, associated with de
novo lipogenesis in the liver [46] and accompanied by insulin
resistance, might in part be reflected by alterations in specific
circulating lipid species in plasma. The lipid profiles observed in
progressors to T2DMmay therefore, in part, reflect the contribu-
tion of fatty liver to the progression of T2DM.
Distribution of FPG levels in the discovery study was
markedly different between the progressors and non-
progressors, which is a limitation of this study. However, the
FPG distributions of the two groups were wider and more
overlapping in the validation set while the lipid models
remained predictive of progression. In spite of the aforemen-
tioned limitation, we presented an analysis of the subset of
the validation set, where the effect of FPG as a confounding
factor was eliminated, leaving only lipid models predictive of
the progression. In the matched normal-FPG subset of the
discovery set, we observed similar or even pronounced effect
sizes compared to the entire discovery set. Since the total
number of T2DM progressors was rather small in the
validation set, it is clear that the findings need to be replicated
in future studies in addition to the validation presented here.
Overall, gender differences in the risk, pathophysiology as
well as complications of T2DM have been reported [47]. Many
factors, including nutrition, lifestyle, and hormonal differ-
ences have been proposed as an explanation. These factors
have some influence on metabolism as well as on levels of
blood lipids andmetabolites [48,49]. In T2DM subjects, the risk
of coronary heart disease (CHD) has been observed [50] to
increase more in women than in men although the incidence
of CHD in non-diabetics is lower in women than in men. The
greater effect of dyslipidemia on the risk of CHD in women
compared to men is hypothesized to be one of the reasons.
This hypothesis could not be tested in this males-only study
and it remains an interesting avenue for future research.
TheMETSIM sample analyzed in the present study is focused
on males, which is both a strength and limitation of the study.
Gender differences can be ruled out as potential confounding
factors in this study setting. On the other hand, the findings
cannot be directly generalized across genders. Some gender
differences in the plasma lipidome are known from earlier
studies [41,51]: Elevated levels of CEs, TGs, ceramides and
LysoPCs have been reported [41] in males compared to females
while the levels of SMs and PSes have been found to be lower in
males. Gender differences in SMs were also reported in another
study [52]. In the females-only DIWA study [53], most TG
species—including TG(54:5) and TG(50:1)—were up-regulated in
T2DM, as we observed in ourmales-only study. Also several PCs,
including PC(36:1) and PC(32:1), showed agreeing changes al-
though they did not reach the level of significance.
There is recent evidence that 1-deoxysphingolipids are
predictive of T2DM progression [54]. These lipids were
previously suggested to be associated with diabetic neurop-
athy but their elevation is seen also before the diagnosis [55].
Interestingly, 1-deoxysphinganine has been demonstrated to
be cytotoxic for pancreatic beta-cells [56]. In our study, SMs
and ceramides were not included in the predictive models.
However, the lipidomics panel used did not include the deoxy
sphingolipids.
11M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 7 8 ( 2 0 1 8 ) 1 – 1 2Given the increasing prevalence of T2DM, there is a demand
for biomarkers that change at a relatively late stage of progres-
sion to T2DM. These biomarkers could make it possible to
identify subjects at the greatest risk of developing the disease.
Specific metabolite biomarkers derived from metabolomic and
lipidomic studies can already now be cost-effectively measured
at the clinic [57]. Taken together, our studyaddsmore evidence to
the hypothesis that plasma lipids can predict progression to
T2DM. We also show that the lipid signature of T2DM is
persistent over time. The complementary nature of the FPG and
lipid predictors suggests that elevated FPG and lipidsmay in part
reflect different underlying pathologies that result in T2DM. Our
findings may therefore pave the way towards a diagnostic
application with the T2DM risk-assessment supported by a
panel of lipids measured routinely at the clinic.Author Contributions
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